Different strategies for cancer treatment: Mathematical modelling

We formulate and analyse a mathematical model describing immune response to avascular tumour under the influence of immunotherapy and chemotherapy and their combinations as well as vaccine treatments. The effect of vaccine therapy is considered as a parametric perturbation of the model. In the case of a weak immune response, neither immunotherapy nor chemotherapy is found to cause tumour regression to a small size, which would be below the clinically detectable threshold. Numerical simulations show that the efficiency of vaccine therapy depends on both the tumour size and the condition of immune system as well as on the response of the organism to vaccination. In particular, we found that vaccine therapy becomes more effective when used without time delay from a prescribed date of vaccination after surgery and is ineffective without preliminary treatment. For a strong immune response, our model predicts the tumour remission under vaccine therapy. Our study of successive chemo/immuno, immuno/chemo and concurrent chemoimmunotherapy shows that the chemo/immuno sequence is more effective while concurrent chemoimmunotherapy is more sparing.

[1]  A. Buzaid,et al.  Practical guidelines for the management of biochemotherapy-related toxicity in melanoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  V. Engelhard,et al.  Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  W. Solbach,et al.  T‐T Cell Interactions during Cytotoxic T Lymphocyte (CTL) Responses: T Cell Derived Helper Factor (Interleukin 2) as a Probe to Analyze CTL Responsiveness and Thymic Maturation of CTL Progenitors , 1980, Immunological reviews.

[4]  S. Rosenberg,et al.  Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated Lymphocytes , 1986 .

[5]  Karol Sikora,et al.  ONCOGENES , 1983, The Lancet.

[6]  A. Diefenbach,et al.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.

[7]  Nicola Bellomo,et al.  A Survey of Models for Tumor-Immune System Dynamics , 1996 .

[8]  L. D. de Pillis,et al.  A cellular automata model of tumor-immune system interactions. , 2006, Journal of theoretical biology.

[9]  M. Nowak,et al.  Oncogenes, anti-oncogenes and the immune response to cancer : a mathematical model , 1992, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[10]  A. Radunskaya,et al.  Mixed Immunotherapy and Chemotherapy of Tumors: Modeling, Applications and Biological Interpretations , 2022 .

[11]  Ami Radunskaya,et al.  A mathematical tumor model with immune resistance and drug therapy: an optimal control approach , 2001 .

[12]  E. Rosenbaum,et al.  Everyone's Guide to Cancer Supportive Care: A Comprehensive Handbook for Patients and Their Families , 2005 .

[13]  E. Bissonette,et al.  Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Longo,et al.  Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Lefever,et al.  A kinetic approach to the immunology of cancer: stationary states properties of effector-target cell reactions. , 1978, Journal of theoretical biology.

[16]  Keith L Black,et al.  Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination , 2004, Clinical Cancer Research.

[17]  Ami Radunskaya,et al.  The dynamics of an optimally controlled tumor model: A case study , 2003 .

[18]  K. Lillehei,et al.  Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[19]  S. Kamidono,et al.  Rejection of Mouse Renal Cell Carcinoma Elicited by Local Secretion of Interleukin‐2 , 1996, Japanese journal of cancer research : Gann.

[20]  Q. Zeng,et al.  Generation of PRL-3- and PRL-1-Specific Monoclonal Antibodies as Potential Diagnostic Markers for Cancer Metastases , 2005, Clinical Cancer Research.

[21]  Mark A J Chaplain,et al.  Mathematical modelling of the spatio-temporal response of cytotoxic T-lymphocytes to a solid tumour. , 2004, Mathematical medicine and biology : a journal of the IMA.

[22]  D. Farquhar,et al.  Mechanism of action and pharmacology studies with DTIC (NSC-45388). , 1976, Cancer treatment reports.

[23]  S N Gardner,et al.  A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. , 2000, Cancer research.

[24]  A. Buzaid,et al.  Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  T. Wheldon Mathematical models in cancer research , 1988 .

[26]  R. Scheuermann,et al.  Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. , 1999, Journal of immunology.

[27]  P Hogeweg,et al.  Macrophage T lymphocyte interactions in the anti-tumor immune response: a mathematical model. , 1985, Journal of immunology.

[28]  D. Kirschner,et al.  A mathematical model of tumor-immune evasion and siRNA treatment , 2003 .

[29]  T. Moritz,et al.  Models for Immunotherapy and Cancer Vaccines , 2007 .

[30]  Markus R. Owen,et al.  MATHEMATICAL MODELLING OF MACROPHAGE DYNAMICS IN TUMOURS , 1999 .

[31]  Alan S. Perelson,et al.  Recruitment Times, Proliferation, and Apoptosis Rates during the CD8+ T-Cell Response to Lymphocytic Choriomeningitis Virus , 2001, Journal of Virology.

[32]  Trachette L. Jackson,et al.  Vascular tumor growth and treatment: Consequences of polyclonality, competition and dynamic vascular support , 2002, Journal of mathematical biology.

[33]  A. Perelson,et al.  Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.

[34]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[35]  K J O'Byrne,et al.  The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. , 2000, European journal of cancer.

[36]  M. O.,et al.  Pattern Formation and Spatiotemporal Irregularity in a Model for Macrophage – Tumour Interactions , 1997 .

[37]  A. Buzaid Strategies for combining chemotherapy and biotherapy in melanoma. , 2000, Cancer control : journal of the Moffitt Cancer Center.

[38]  Stephanie Forrest,et al.  A stochastic model of cytotoxic T cell responses. , 2004, Journal of theoretical biology.

[39]  A. Murugan,et al.  Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls. , 2007, Mathematical biosciences.

[40]  C. Giachino,et al.  Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity? , 2005, Pigment cell research.

[41]  G. Griffiths,et al.  Development of humanized antibodies as cancer therapeutics. , 2005, Methods.

[42]  M. Sznol,et al.  Antibodies and Recombinant Cytokines , 2005 .

[43]  M. Chaplain,et al.  Travelling-wave analysis of a model of the immune response to cancer. , 2004, Comptes rendus biologies.

[44]  J. Trempe Molecular biology of the cell, 3rd edition Bruce Alberts, Dennis Bray, Julian Lewis, Martin Raff, Keith Roberts and James D. Watson, Garland Publishing, 1994, 559.95 (xiii + 1294 pages), ISBN 0-815-31619-4 , 1995, Trends in Endocrinology & Metabolism.

[45]  D. Kirschner,et al.  Modeling immunotherapy of the tumor – immune interaction , 1998, Journal of mathematical biology.

[46]  Jon Ernstberger,et al.  OPTIMAL CONTROL APPLIED TO IMMUNOTHERAPY , 2003 .

[47]  V. Osipov,et al.  Modeling of anti-tumor immune response: immunocorrective effect of weak centimeter electromagnetic waves , 2005, q-bio/0506006.

[48]  Zhiwei Hu,et al.  Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. , 1999, Proceedings of the National Academy of Sciences of the United States of America.